Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7771950 vs Tucatinib in HER2-Positive Breast Cancer (BREnnA)
NCT07413939Phase 3Recruiting
- Sponsor
- Roche
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of RO7771950 in breast cancer (3 arms), sponsored by Roche. Primary endpoint: Progression-free Survival at 35 months. Started May 2026; status: recruiting.
02
Drugs
RO7771950
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07413939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413939.